Health Canada begins regulating drug access in Montreal
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Health Canada has begun implementing drug access regulations in Montreal. These regulations are part of a larger effort by Health Canada to set new standards for businesses operating in Montreal. Separately, Health Canada authorized PrSIBBORAN, an ultra-short-acting beta-1 adrenergic receptor blocker, in 2023 for use in acute-care settings.
From finanznachrichten.de
Why it matters
The new regulations affect how drug access is managed within Montreal. PrSIBBORAN is indicated for the short-term reduction of ventricular rate in patients with conditions such as supraventricular tachycardia. The regulatory action impacts the operational capacity of health networks in the region.
Health Canada is setting new standards enforced by the Canadian Food Inspection Agency for businesses operating in Montreal.
From finanznachrichten.de
Who's involved
- Health CanadaDepartment overseeing public health and setting drug access regulations
- MontrealThe city where Health Canada is exercising regulatory oversight over drug access
- Government of CanadaThe federal government under which Health Canada operates
Keep exploring
The entities involved
-
Health Canada
Department of the Canadian Government that oversees public health
-
Montreal
largest city in Quebec, Canada